1,839 Shares in Stryker Co. (NYSE:SYK) Purchased by Heck Capital Advisors LLC

Heck Capital Advisors LLC purchased a new position in shares of Stryker Co. (NYSE:SYK - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,839 shares of the medical technology company's stock, valued at approximately $662,000.

Several other hedge funds have also added to or reduced their stakes in SYK. Kohmann Bosshard Financial Services LLC purchased a new position in Stryker during the 4th quarter worth $25,000. Rakuten Securities Inc. lifted its holdings in Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC purchased a new position in Stryker during the fourth quarter valued at approximately $30,000. BankPlus Trust Department purchased a new stake in shares of Stryker in the fourth quarter worth $33,000. Finally, Activest Wealth Management purchased a new position in shares of Stryker during the fourth quarter worth about $36,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

SYK has been the subject of a number of analyst reports. BTIG Research set a $403.00 price objective on Stryker and gave the company a "buy" rating in a research note on Monday, April 14th. Truist Financial lifted their price target on Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research report on Monday, May 5th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Needham & Company LLC reiterated a "buy" rating and issued a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. Finally, Barclays boosted their price objective on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and an average price target of $427.30.

Stryker Price Performance

Shares of Stryker stock traded up $0.51 during trading on Friday, reaching $382.86. The company's stock had a trading volume of 1,993,145 shares, compared to its average volume of 1,342,825. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business has a 50 day moving average price of $368.77 and a 200-day moving average price of $376.22. The company has a market capitalization of $146.13 billion, a P/E ratio of 49.34, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. During the same period in the previous year, the company earned $2.50 EPS. Stryker's revenue for the quarter was up 11.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker's dividend payout ratio is currently 45.41%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.